Shares of InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, experienced a significant surge of 7.60% on November 6, 2024. This rally was fueled by a thorough analysis of the company's financial performance, which revealed that InMode's earnings potential might be stronger than initially perceived.

The analysis focused on InMode's accrual ratio, a crucial metric used to assess a company's ability to convert reported profits into free cash flow (FCF). With an impressive accrual ratio of -0.15 for the year to September 2024, InMode demonstrated a remarkable cash conversion rate. Notably, the company's free cash flow of $161 million in the last year significantly exceeded its statutory profit of $153.7 million.

This positive cash flow situation suggests that InMode's earnings potential may be better than initially perceived by the market. Investors reacted favorably to the analysis, driving the stock's surge as they reevaluated the company's financial strength and future prospects. Analysts and market experts believe that this robust cash flow generation could bolster InMode's growth initiatives and enhance shareholder value over the long term.